



Intercell receives "The Vaccine Industry Excellence Award"

- » Intercell's Hepatitis C vaccine candidate was awarded in the category of "Best New Therapeutic Vaccine" at the World Vaccine Congress
- » Intercell's therapeutic Hepatitis C vaccine successfully concluded Phase II clinical trials in February 2008

Vienna (Austria), April 24, 2008 – In the course of the World Vaccine Congress in Washington D.C., USA, Intercell was awarded "The Vaccine Industry Excellence Award" in the category "Best New Therapeutic Vaccine" for its therapeutic Hepatitis C (HCV) vaccine candidate.

Earlier this year, Intercell's therapeutic vaccine candidate against HCV successfully concluded Phase II clinical trials. The novel vaccine is designed to stimulate T-cell responses against viral protein structures conserved throughout the major HCV genotypes in order to reduce viral load in the blood of chronically infected patients.

"We are pleased to receive this award for our novel therapeutic Hepatitis C vaccine. The latest Phase II data provides a strong base to further strengthen our Hepatitis C franchise and to accelerate our efforts towards a most valuable potential component in a combination treatment for HCV," stated Alexander von Gabain, Chief Scientific Officer of Intercell.

To improve and accelerate the development of a therapeutic Hepatitis C vaccine, Intercell and its partner Novartis will take advantage of an enlarged antigen portfolio and of IC31®, Intercell's second-generation adjuvant.

With representatives from over 200 individual companies, the "World Vaccine Congress", taking place in Washington D.C. (USA) from April 21-24, 2008, is one of the largest and most important vaccine industry meetings this year.

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006. The Market Authorization





Application (MAA) in Europe as well as the Biological License Application (BLA) with the US Food and Drug Administration (FDA) for the use of the vaccine to prevent Japanese Encephalitis were submitted in December of 2007. The licensure application to TGA (Therapeutic Goods Administration) in Australia was submitted in February of 2008.

The company's broad development pipeline includes a partnered *S. aureus* vaccine in Phase II, a therapeutic vaccine against Hepatitis C in Phase II, a *Pseudomonas* vaccine in Phase II, a partnered Tuberculosis vaccine (Phase I/II), and five products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna Stock Exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG:

Lucia Malfent
Head of Corporate Communications
Campus Vienna Biocenter 2, A-1030 Vienna
P: +43-1-20620-303
Mail to: LMalfent@intercell.com

This communication expressly or implicitly contains certain advance statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such advance statements. Intercell AG is providing this communication as of this date and does not update any advance statements contained herein as a result of new information, future events or otherwise.